This invention discloses an engineered strain of
Streptococcus suis Δ07335-hSLY (classification name:
Streptococcus suis Δ07335-hSLY, deposit date: May 13, 2026, deposit number: CCTCC NO: M2026937), its construction method, and applications, relating to the fields of
microbial genetic engineering and
drug screening technology. This invention uses
Streptococcus suis SC19 strain as the starting strain and obtains the engineered strain SC19Δ07335 by knocking out the 07335
gene in its
genome using
homologous recombination technology. Compared with the starting strain SC19, the expression level of the
hemolysin SLY
gene in this engineered strain is significantly upregulated, increasing the success rate of the
hemolysis test in the culture supernatant from 30% to 100%. Simultaneously, the expression of the capsular
polysaccharide synthesis
gene CPS is downregulated, the
capsule becomes thinner, and the
in vivo virulence is significantly reduced. The anti-hemolytic
active compound screening
system established based on this engineered strain is stable and reliable, and compounds with anti-SLY activity, such as
baicalin, have been successfully screened. Animal experiments have verified that the
survival rate of mice in the medium and high
dose treatment groups of
baicalin reached 100%.